argenx SE

Change company Symbol lookup

Select an option...

ARGX argenx SE

ENZC Enzolytics Inc

GREE Greenidge Generation Holdings Inc

MLM Martin Marietta Materials Inc

ERESW East Resources Acquisition Equity Warrant Exp 1st July 2027 *W EXP 07/01/2027

NRAC Noble Rock Acquisition Corp

DCGO DocGo Inc

VELOW Velocity Acquisition Equity Warrant Exp 24 Feb 2028 *W EXP 02/24/2028

MRC MRC Global Inc

BAC Bank of America Corp

Go

argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.

ADR Fees

American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees